5 Key Takeaways
-
1
OCS-01 eye drops demonstrated significant improvements in best-corrected visual acuity and retinal thickness in DME patients at 12 weeks.
-
2
The DIAMOND-1 trial involved 148 patients randomized to receive OCS-01 or a vehicle control, assessing efficacy over a 12-week period.
-
3
Patients treated with OCS-01 gained a mean of 7.2 ETDRS letters at week 6, significantly higher than the 3.1 letters gained by the control group.
-
4
Reductions in retinal thickness were observed, with treatment-naïve eyes showing a mean decrease of 71 μm after OCS-01 treatment.
-
5
OCS-01 was well tolerated, with no serious adverse events reported, supporting its potential as a noninvasive treatment for DME.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.